print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST
04/02/2015 (Added to site)
Author(s): Quaglino, P.; Matthiessen, L. W.; Curatolo, P.; Muir, T.; Bertino, G.; Kunte, C.; Odili, J.; Rotunno, R.; Humphreys, A. C.; Letulé, V.; Marenco, F.; Cuthbert, C.; Albret, R.; Benazzo, M.; De Terlizzi, F.; Gehl, J.

Predicting patients at risk for pain associated with electrochemotherapy

Journal: Acta Oncologica, early-online (2015), pp. 1-6
DOI: 10.3109/0284186X.2014.99254
Tell your friend  | 

Abstract:

Background. Electrochemotherapy describes the use of electric pulses to enhance chemotherapy uptake, and has proven highly efficient in treating cutaneous metastases. Patients referred for electrochemotherapy present with diverse clinical pictures, from multiple small lesions to large, ulcerated lesions. Post-electrochemotherapy pain has been observed in some patients. The objectives of this study were to evaluate pain scores before and after electrochemotherapy, and to investigate if patients at risk of post-procedure pain could be identified.

Methods. Seven cancer centres in the International Network for Sharing Practices on Electrochemotherapy (INSPECT) consecutively and prospectively reported to a common database. Electrochemotherapy consisted of intratumoural or intravenous injection of bleomycin, followed by delivery of electric pulses in local or general anesthesia.

Results. Of 121 patients 39% had metastatic melanoma, 18% squamous cell carcinoma, 16% breast cancer, 13% basalcell carcinoma, and 14% other malignancies. Median size of the largest nodules was 2.3 cm (range 0.3 – 40 cm). A majority of patients presented with low pain scores, and this continued through follow-up (74%). A subset of patients had moderate (13%) or severe pain (13%) after treatment. Post-procedure pain was statistically signifi cantly associated with: 1) moderate or severe pain before treatment (p  0.0001); 2) size of the largest treated lesion (p  0.01); 3) previous irradiation (p  0.02); and 4) high treatment current value (p  0.0001).

Conclusion. The majority of patients had no or mild pain after electrochemotherapy. Patients at risk for post-procedure pain could be identifi ed at the pre-treatment visit, and/or at the time of treatment, enabling a pain management strategy for this group.



Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: